ADMA Quote, Financials, Valuation and Earnings

Aldeyra Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of --. ADMA Biologics, Inc.'s return on equity of 58.71% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 33.13%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 82.05%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. ADMA Biologics, Inc.'s net income of $36.4M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.64x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.71x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Arcutis Biotherapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 7.47%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 33.13%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 9.17%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.693, suggesting its more volatile than the S&P 500 by 69.345%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.64x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.71x versus 11.64x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Marker Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -162.11%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 33.13%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.33 which suggests that it could grow by 411.03%. Given that Marker Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.977%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.64x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.71x versus 3.89x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -40.15%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 33.13%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 66.9%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than ADMA Biologics, Inc..

ADMA Biologics, Inc. has a beta of 0.433, which suggesting that the stock is 56.749% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 22.64x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 9.71x versus 1.95x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.